Cargando…

Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials

BACKGROUND: The extent of lung involvement visualized by high-resolution computed tomography (HRCT) is a predictor of decline in forced vital capacity (FVC) in scleroderma–interstitial lung disease. Our objective was to evaluate the performance of three different HRCT-defined staging systems in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Khanna, Dinesh, Nagaraja, Vivek, Tseng, Chi-hong, Abtin, Fereidoun, Suh, Robert, Kim, Grace, Wells, Athol, Furst, Daniel E., Clements, Philip J., Roth, Michael D., Tashkin, Donald P., Goldin, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718035/
https://www.ncbi.nlm.nih.gov/pubmed/26704522
http://dx.doi.org/10.1186/s13075-015-0872-2
_version_ 1782410727209828352
author Khanna, Dinesh
Nagaraja, Vivek
Tseng, Chi-hong
Abtin, Fereidoun
Suh, Robert
Kim, Grace
Wells, Athol
Furst, Daniel E.
Clements, Philip J.
Roth, Michael D.
Tashkin, Donald P.
Goldin, Jonathan
author_facet Khanna, Dinesh
Nagaraja, Vivek
Tseng, Chi-hong
Abtin, Fereidoun
Suh, Robert
Kim, Grace
Wells, Athol
Furst, Daniel E.
Clements, Philip J.
Roth, Michael D.
Tashkin, Donald P.
Goldin, Jonathan
author_sort Khanna, Dinesh
collection PubMed
description BACKGROUND: The extent of lung involvement visualized by high-resolution computed tomography (HRCT) is a predictor of decline in forced vital capacity (FVC) in scleroderma–interstitial lung disease. Our objective was to evaluate the performance of three different HRCT-defined staging systems in the Scleroderma Lung Study I (SLS I) over a 1-year period. METHODS: We assessed two visual semiquantitative scores: the maximum fibrosis score (MaxFib, the fibrosis score in the zone of maximal lung involvement) and visual assessment of total lung involvement (TLI) as proposed by Goh and Wells. In addition, we evaluated the computer-aided diagnosis and calculated the quantitative percentage with fibrosis (QLF) and TLI. RESULTS: The mean duration of the disease was 3.2 years, and the mean FVC was 67.7 %. Regardless of the staging system used, a greater degree of fibrosis/TLI on HRCT scans was associated with a greater decline in FVC in the placebo group. Using the MaxFib and QLF, the mean absolute changes in FVC from baseline were 0.1 % and −1.4 %, respectively, in <25 % lung involvement vs. a change of −6.2 % and −6.9 %, respectively, with >25 % involvement (negative score denotes worsening in FVC). Conversely, cyclophosphamide was able to stabilize decline in FVC in subjects with greater degree of involvement detected by HRCT. Using the visual MaxFib and QLF, the mean absolute improvements in FVC were 1.2 and 1.1, respectively, with >25 % involvement. CONCLUSIONS: HRCT-defined lung involvement was a predictor of decline in FVC in SLS I. The choice of staging system for cohort enrichment in a clinical trial depends on feasibility. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00004563 (Scleroderma Lung Study I) ISRCTN15982171. Registered 19 Aug 2015. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-015-0872-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4718035
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47180352016-01-20 Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials Khanna, Dinesh Nagaraja, Vivek Tseng, Chi-hong Abtin, Fereidoun Suh, Robert Kim, Grace Wells, Athol Furst, Daniel E. Clements, Philip J. Roth, Michael D. Tashkin, Donald P. Goldin, Jonathan Arthritis Res Ther Research Article BACKGROUND: The extent of lung involvement visualized by high-resolution computed tomography (HRCT) is a predictor of decline in forced vital capacity (FVC) in scleroderma–interstitial lung disease. Our objective was to evaluate the performance of three different HRCT-defined staging systems in the Scleroderma Lung Study I (SLS I) over a 1-year period. METHODS: We assessed two visual semiquantitative scores: the maximum fibrosis score (MaxFib, the fibrosis score in the zone of maximal lung involvement) and visual assessment of total lung involvement (TLI) as proposed by Goh and Wells. In addition, we evaluated the computer-aided diagnosis and calculated the quantitative percentage with fibrosis (QLF) and TLI. RESULTS: The mean duration of the disease was 3.2 years, and the mean FVC was 67.7 %. Regardless of the staging system used, a greater degree of fibrosis/TLI on HRCT scans was associated with a greater decline in FVC in the placebo group. Using the MaxFib and QLF, the mean absolute changes in FVC from baseline were 0.1 % and −1.4 %, respectively, in <25 % lung involvement vs. a change of −6.2 % and −6.9 %, respectively, with >25 % involvement (negative score denotes worsening in FVC). Conversely, cyclophosphamide was able to stabilize decline in FVC in subjects with greater degree of involvement detected by HRCT. Using the visual MaxFib and QLF, the mean absolute improvements in FVC were 1.2 and 1.1, respectively, with >25 % involvement. CONCLUSIONS: HRCT-defined lung involvement was a predictor of decline in FVC in SLS I. The choice of staging system for cohort enrichment in a clinical trial depends on feasibility. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00004563 (Scleroderma Lung Study I) ISRCTN15982171. Registered 19 Aug 2015. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-015-0872-2) contains supplementary material, which is available to authorized users. BioMed Central 2015-12-23 2015 /pmc/articles/PMC4718035/ /pubmed/26704522 http://dx.doi.org/10.1186/s13075-015-0872-2 Text en © Khanna et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Khanna, Dinesh
Nagaraja, Vivek
Tseng, Chi-hong
Abtin, Fereidoun
Suh, Robert
Kim, Grace
Wells, Athol
Furst, Daniel E.
Clements, Philip J.
Roth, Michael D.
Tashkin, Donald P.
Goldin, Jonathan
Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials
title Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials
title_full Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials
title_fullStr Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials
title_full_unstemmed Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials
title_short Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials
title_sort predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718035/
https://www.ncbi.nlm.nih.gov/pubmed/26704522
http://dx.doi.org/10.1186/s13075-015-0872-2
work_keys_str_mv AT khannadinesh predictorsoflungfunctiondeclineinsclerodermarelatedinterstitiallungdiseasebasedonhighresolutioncomputedtomographyimplicationsforcohortenrichmentinsystemicsclerosisassociatedinterstitiallungdiseasetrials
AT nagarajavivek predictorsoflungfunctiondeclineinsclerodermarelatedinterstitiallungdiseasebasedonhighresolutioncomputedtomographyimplicationsforcohortenrichmentinsystemicsclerosisassociatedinterstitiallungdiseasetrials
AT tsengchihong predictorsoflungfunctiondeclineinsclerodermarelatedinterstitiallungdiseasebasedonhighresolutioncomputedtomographyimplicationsforcohortenrichmentinsystemicsclerosisassociatedinterstitiallungdiseasetrials
AT abtinfereidoun predictorsoflungfunctiondeclineinsclerodermarelatedinterstitiallungdiseasebasedonhighresolutioncomputedtomographyimplicationsforcohortenrichmentinsystemicsclerosisassociatedinterstitiallungdiseasetrials
AT suhrobert predictorsoflungfunctiondeclineinsclerodermarelatedinterstitiallungdiseasebasedonhighresolutioncomputedtomographyimplicationsforcohortenrichmentinsystemicsclerosisassociatedinterstitiallungdiseasetrials
AT kimgrace predictorsoflungfunctiondeclineinsclerodermarelatedinterstitiallungdiseasebasedonhighresolutioncomputedtomographyimplicationsforcohortenrichmentinsystemicsclerosisassociatedinterstitiallungdiseasetrials
AT wellsathol predictorsoflungfunctiondeclineinsclerodermarelatedinterstitiallungdiseasebasedonhighresolutioncomputedtomographyimplicationsforcohortenrichmentinsystemicsclerosisassociatedinterstitiallungdiseasetrials
AT furstdaniele predictorsoflungfunctiondeclineinsclerodermarelatedinterstitiallungdiseasebasedonhighresolutioncomputedtomographyimplicationsforcohortenrichmentinsystemicsclerosisassociatedinterstitiallungdiseasetrials
AT clementsphilipj predictorsoflungfunctiondeclineinsclerodermarelatedinterstitiallungdiseasebasedonhighresolutioncomputedtomographyimplicationsforcohortenrichmentinsystemicsclerosisassociatedinterstitiallungdiseasetrials
AT rothmichaeld predictorsoflungfunctiondeclineinsclerodermarelatedinterstitiallungdiseasebasedonhighresolutioncomputedtomographyimplicationsforcohortenrichmentinsystemicsclerosisassociatedinterstitiallungdiseasetrials
AT tashkindonaldp predictorsoflungfunctiondeclineinsclerodermarelatedinterstitiallungdiseasebasedonhighresolutioncomputedtomographyimplicationsforcohortenrichmentinsystemicsclerosisassociatedinterstitiallungdiseasetrials
AT goldinjonathan predictorsoflungfunctiondeclineinsclerodermarelatedinterstitiallungdiseasebasedonhighresolutioncomputedtomographyimplicationsforcohortenrichmentinsystemicsclerosisassociatedinterstitiallungdiseasetrials